Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 4512345...102030...Last »

FDA clears AstraZeneca’s lung cancer immunotherapy

The U.S. FDA granted approval for expanded use of AstraZeneca‘s immunotherapy drug Imfinzi to treat non-small cell lung cancer whose tumors can not be surgically removed.

Read More »

Merck KGaA, Pfizer’s immunotherapy fails in lung cancer trial

Merck KGaA and Pfizer Inc. received a setback for their drug Bavencio, which is a late starter in the cancer immunotherapy field.

Read More »

EU Approves Celltrion’s Trastuzumab Biosimilar

The EC approved Herzuma for patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have HER2 overexpression or HER2 gene amplification.

Read More »

Eisai’s Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet

Eisai Co. Ltd. announced that the results of a Phase III study of its in-house discovered and developed anticancer agent lenvatinib mesylate in patients with hepatocellular carcinoma were published in the online version of The Lancet.

Read More »

Roche wins UK watchdog’s nod for lymphoma drug

Britain’s healthcare watchdog NICE recommended Roche’s medicine Gazyvaro for previously untreated advanced follicular lymphoma patients after initially rejecting the medicine in 2017.

Read More »

Janssen Submits MAA for Apalutamide

J&J’s Janssen Pharmaceutical Companies submitted a Marketing Authorization Application to the EMA for apalutamide for non-metastatic castration-resistant prostate cancer.

Read More »

Sanofi Abandons Multiple Mid-Stage Drug Programs

As part of the company’s fourth-quarter 2017 earnings report, Paris-based Sanofi released a pipeline update showing it plans to halt several mid-stage drug programs.

Read More »

Regeneron CEO says fears over Eylea ‘greatly exaggerated‘

Fears of the demise of blockbuster eye drug Eylea were “greatly exaggerated,” Regeneron Pharmaceuticals Inc.’s chief executive said after the treatment and new eczema drug Dupixent powered the company’s fourth-quarter 2017 results.

Read More »

Array melanoma drugs show significant survival vs Roche drug in study

A combination of experimental drugs from Array BioPharma Inc. kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late-stage study.

Read More »

Xtandi delays prostate cancer spread in early-stage disease

Use of Xtandi in early-stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone.

Read More »

Genentech’s Tecentriq and Avastin combo met co-primary endpoint in late-stage study for advanced kidney cancer

Genentech announced results from the positive Phase III IMmotion151 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.

Read More »

Three Small CRISPR Biotechs That Could Cure 10,000 Diseases

Investor’s Business Daily looked at three small biotech companies that appear to be leading the CRISPR race.

Read More »

Bristol-Myers’ Lung Cancer Combo Wows in Phase III

Shares of Bristol-Myers Squibb climbed after announcing its anticipated Phase III CheckMate-227 study met its endpoints of progression-free survival as a first-line lung cancer treatment.

Read More »

AstraZeneca Posts Disappointing 2017 Financials

AstraZeneca saw revenues and product sales fall over the course of 2017. Total revenues declined 2 percent to $22.46 billion and product sales fell 5 percent to $20.15 billion.

Read More »

AstraZeneca links with Alibaba and Tencent in China

AstraZeneca clinched two new deals with Chinese tech giants Alibaba and Tencent as the British drugmaker steps up the company’s drive to expand business in China.

Read More »

AstraZeneca is sued by Array BioPharma

Array BioPharma sued AstraZeneca, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co.

Read More »

Partner Therapeutics Nabs $60 Million, Acquires Leukine From Sanofi

One week after launching, Partner Therapeutics acquired the global rights to Leukine (sargramaostin) from Paris-based Sanofi.

Read More »

Roche Cuts Early, Late-Stage Drug Candidates

First reported by FierceBiotech, Roche’s financial reports indicated the company was cutting a total of four drugs: One late-stage product and three drugs in Phase I development.

Read More »

Seattle Genetics Snaps Up Cascadian in $614 Million Buyout Deal

Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.

Read More »

Global cancer survival rates improve, but wide gaps remain

Cancer patients’ survival prospects are improving – even for some of the deadliest types such as lung cancer – but there are huge disparities between countries, particularly for children, according to a published study.

Read More »

Page 1 of 4512345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation